| Catalog No. | Size | Price (USD) |
| 15691-MM11-50 | 50 µL | $147.96 |
| 15691-MM11-100 | 100 µL | $251.64 |
| 15691-MM11-200 | 200 µL | $355.32 |
General Information
| Product name | Anti-CDNF Antibody, Mouse Monoclonal |
| Validated applications | ELISA (FAQ Protocol) |
| Species reactivity | Reacts with: Human |
| Specificity | Human CDNF |
| Immunogen | Recombinant Human CDNF / ARMETL1 Protein (Catalog#15691-H08H) |
| Preparation | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human CDNF / ARMETL1 (rh CDNF / ARMETL1; Catalog#15691-H08H; NP_001025125.2; Met1-Leu187). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography. |
| Source | Monoclonal Mouse IgG2b Clone #11 |
| Purification | Protein A |
| Formulation | 0.2 μm filtered solution in PBS |
| Conjugate | Unconjugated |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
Synonyms: Anti-ARMETL1 Antibody
Background Information
| Full Name | cerebral dopamine neurotrophic factor |
| Description | Cerebral Dopamine Neurotrophic Factor (CDNF), also known as ARMETL1 (ARMET-like protein 1), is a secreted protein with eight conserved cysteine residues, predicting a unique protein fold and defining a new, evolutionarily conserved protein family. CDNF is a novel neurotrophic factor with strong trophic activity on dopaminergic neurons comparable to that of glial cell line-derived neurotrophic factor (GDNF). CDNF/ARMETL1 is a evolutionary conserved protein which can protect and restore the function of dopaminergic neurons in the rat model of Parkinson's disease, suggesting that CDNF might be beneficial for the treatment of Parkinson's disease. CDNF is widely expressed in neurons in several brain regions including cerebral cortex, hippocampus, substantia nigra, striatum and cerebellum. Human CDNF is glycosylated and secreted from transiently transfected cells. CDNF promotes the survival, growth, and function of dopamine-specific neurons and is expressed in brain regions that undergo cocaine-induced neuroplasticity. |
| References |
|
title: Recombinant AAV vectors for treating neurodegenerative disorders
authors: Yezheng Tao; Shin-Shay Tian; Xiaoping Zhao
date: 2026-04-21
cited_by_count: 0
techniques: Construct
bioz_score: 94
